Diabetic Nephropathy

Diabetic Retinopathy Predicts Higher CKD Progression Risk

Publish Date March 6, 2019

Proliferative vs non-proliferative diabetic retinopathy in CKD patients is associated with a higher risk of CKD progression.

Kidney Failure Risk Minimal Following Diabetes Diagnosis

Publish Date February 1, 2019

In a Finnish study, the cumulative risk for end-stage renal disease among patients with newly diagnosed with type 2 diabetes was less than 1% at 20 years.

Treating Albuminuria Reduces CV Events, Death in Type 2 Diabetes

Publish Date January 30, 2019

Suppressing albuminuria should be an important target of therapy, according to investigators.

SGLT2 Inhibitors May Reduce CV, Renal Risks in Type 2 Diabetes

Publish Date November 21, 2018

SGLT2i reduced the risks for progression of renal disease by 45% and heart failure hospitalization by 31% in patients with type 2 diabetes.

Bardoxolone Methyl Leads to Weight Loss in T2D With Concurrent Chronic Kidney Disease

Publish Date November 6, 2018

Treatment with bardoxolone methyl resulted in significant weight loss and showed no evidence of muscle wasting in patients with type 2 diabetes and stage IV chronic kidney disease.

Aggressive Control of BP, Lipids in T2DM May Up Kidney Risk

Publish Date November 5, 2018

Strict BP control, fenofibrate use may increase long-term risk for adverse kidney events in T2DM patients

Sitagliptin Better for Glycemic Control in T2D With Renal Impairment

Publish Date October 15, 2018

Study results indicated that sitagliptin showed greater glycemic efficacy than dapagliflozin treatment.

ADA, EASD Issue New Recommendations for T2DM

Publish Date October 11, 2018

Additional focus on lifestyle management, self-management education and support emphasized

Canagliflozin Trial for T2D, CKD Halted Due to Positive Results

Publish Date July 26, 2018

A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.

Trulicity Labeling Updated to Include Data on T2D Patients With CKD

Publish Date July 20, 2018

In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received traditional basal-bolus insulin.